Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.

By A. Ullmann, J. Lipton, D. Vesole, P. Chandrasekar, A. Langston, S. Tarantolo, H. Greinix, Wellington Morais de Azevedo, V. Reddy, N. Boparai and 3 more. New England Journal of Medicine, 2007

1,273 citations recorded by the source corpus.

Subfields: Hematology, Infectious Diseases, Oncology

View Paper: https://www.semanticscholar.org/paper/dfb0436cab20d325fc825d51539e982fd183ed88

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Infectious Diseases

1. D. Kontoyiannis
2. J. Perfect
3. J. Fishman
4. E. Anaissie
5. M. Pfaller
6. D. Diekema

In Oncology

1. J. Fishman

Citations in the corpus

• Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. (2016, background): “ing fluconazole, which has no mold activity [254].”
• Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America (2009, background): “After transplantation, posaconazole was shown to be more effective than fluconazole in preventing invasive fungal infections in stem cell transplant recipients who had severe graft-versus-host disease [126].”
• Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. (2008, background): “efficacy, in strategy trials [2–6], for the formulation of clinical”
• Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplant Recipients: A Global Perspective (2009, background): “Few HCT recipients require prophylaxis against Candida in the postengraftment period (phases II and III), but if needed (eg, because of the presence of GVHD), options include voriconazole (BI) [430] and posaconazole (BI) [429].”
• Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. (2008, result): “A separate study of posaconazole prophylaxis during GVHD in HSCT recipients also found a significant reduction in proven and probable invasive fungal infections and similar toxicity in posaconazole recipients, compared with those receiving fluconazole [104].”